Provectus is a clinical-stage biotechnology company focused on developing immunotherapy medicines based on small molecules known as halogenated xanthenes, of which the company owns the entire class. In Provectus, the lead molecule is called "Rose Bengal Disodium." Clinical and non-clinical data suggest that Provectus' drug platform may be used to treat a variety of diseases, including oncology, dermatology, hematology, virology, microbiology, and ophthalmology.

Provecctus is a rare disorder that affects the bones. It often starts with pain in the bones and muscles, but can turn into more serious health problems like fractures or even cancer.